Peptide Deformalase (PDF) Inhibitors
Since 1940, penicillin has been used in medicine, Antibacterials have been developing to more than a thousand and hundreds of them are widely used in medicine. With multiply drug-resistant strains and emergency of pathogens and biothreat organisms, "Physicians interviewed unanimously agree that agents with novel mechanisms of action are greatly needed–particularly agents that are effective against multidrug-resistant gram-negative pathogens–to ensure the availability of sufficient options to treat bacterial infections over the next 10 years." The total world market for antibiotics in 2002 was over $26bn. In 1995, the complete DNA sequence of a bacterial genome from haemophilus influenzae was determined. The prospect of hundreds of new genes to explore as possible targets sparked new interest in antibacterial discovery and fired the imagination. Embracing the genomics approach, evaluate enough genes for their potential as targets for novel antibacterials and high-throughput screen campaigns of individual targets. In total, high-throughput screening (HTS) campaigns of individual targets, complete macromolecular biosynthetic pathways and whole-cell screens were run against our synthetic chemical collection at that time.

The cooperation between CMS Group and Bioleap, LLC (New Hope, PA, USA) is to find a novel antibacterial compound that has either Gram-positive or broad-spectrum activity. Taking advantages of low cost and short duration R&D in China, depending on our established R&D platform and experienced R&D team, CMS Group can undertake all the pre-clinical studies and clinical trials that are necessary to obtain regulatory approval in China. With the combined efforts from the two companies, we have opportunities to develop novel PDF inhibitors faster, better and at lower costs.